Guess what Gilead's up to?
Gilead and Kite are acquiring a new company that will help them expand research and development into cellular therapy. Source - ASPost-Gilead
Trending Content - Off Topic Forum
| +25 | Alcoholism | 7 | 20h |
| +23 | What do you think of tiktoker Jinginvests | 9 | 2d |
| +17 | Press Secretary had shortest stint EVER | 1 | 39m |
| +14 | How Are Cornell 7 / GC Members Affecting Your Bank or Firm? | 5 | 6d |
| +14 | PWP Piper deal terminated, ruined my chances with a girl | 5 | 3h |
| +11 | Del | 2 | 3d |
| +3 | Being able to DnD is God Mode | 3 | 1d |
| +2 | Which IB Target School Has the Hottest Girls? | 3 | 23h |
| 0 | Schools That Used To Be Targets But Are Now Semi-Targets? (or worse...) | 1 | 14h |
Career Resources
Gilead is definitely undervalued at its current price.
Sciences?
Good guess?
I got in Gilead at around $72** a share, and have researched this for quite some time (made a post about the KITE acquisition).
What I love about the stock is 1) Low P/E ratio 2) 2.8% Dividend Yield. They have a PDUFA in February (I believe) for TAF, I believe the stock will rally into it but will sell off; buy the rumour sell the fact. It will be amazing for their HIV revenues.
Gilead has an insane amount of money in hand that's offshore, tax issues can rise here. Another issue is their HCV revenue which have been declining. The real money is in their HIV pipeline (20-25% of the HIV market) which has been growing, their acquisition of KITE (which was a steal) will get them in the Oncology game. Right then and there that's 3 cash flows.
I am very questionable of their HCV revenues though which are pretty bad. Their approval of Sovaldi in China should boost their sales since there is quite a bit of demand from the population
There are many oppurtunities in the market right which are, quite frankly, much better than biotechnology. I am interested to seeing if my thesis plays out in the coming years. If anyone cures HIV, it will be Gilead
.
Are you basing the deal strictly off numbers? I think getting their foot in oncology will be big for them in the future. I try to look at it from a qualitative standpoint.
.
Yeah, I too think they paid a tad too much for Kite.
Inventore dolorem perspiciatis provident quo enim et distinctio. Ab aut nesciunt dolores velit. Architecto sequi quo quidem sit sed facilis veniam. Illo mollitia quis blanditiis sapiente dolor minus atque. Sint voluptatem qui pariatur.
Et architecto veritatis quibusdam animi. Officiis incidunt excepturi exercitationem.
Tempore qui repellendus qui recusandae. Atque iste consequuntur ratione modi corporis inventore. Porro eum maiores voluptatum voluptatum ut delectus.
Consequatur sit dolore est alias. Sequi voluptas dolorem culpa repudiandae vel non dolor. Voluptatem praesentium et itaque id doloribus quam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...